* Pulmonx Corp LUNG.OQ LUNG.O is expected to show a rise in
quarterly revenue when it reports results on November 2.
* The Redwood City, California-based company is expected to
report a 24.2% increase in revenue to $13.178 million from
$10.61 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pulmonx Corp is for a
loss of 37 cents per share. For the same quarter last year, the
company reported a loss of $2.26 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Pulmonx Corp is
$54.5, about 28.6% above its last closing price of $38.93.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.37 -0.37 -0.34 Beat 8.6
Mar. 31 2021 -0.38 -0.38 -0.34 Beat 10.1
Dec. 31 2020 -0.28 -0.28 -0.27 Beat 2.9
Sep. 30 2020 -4.32 -4.32 -2.26 Beat 47.7
This summary was machine generated October 30 at 02:01 GMT. All
figures in US dollars unless otherwise stated